Economic Analyses of the REDUCE Trial
|ClinicalTrials.gov Identifier: NCT01337258|
Recruitment Status : Completed
First Posted : April 18, 2011
Last Update Posted : May 30, 2017
The objective of this project is to conduct a retrospective economic analysis of the use of dutasteride for the prevention of prostate cancer based on data from the REDUCE clinical trial. REDUCE is a 4-year, phase 3, randomized, double-blind, parallel assignment clinical trial of the use of dutasteride compared with no chemopreventive treatment.
The REDUCE trial was a four-year, international, multicenter, randomized, double-blind, placebo-controlled, parallel group study. There were 790 investigators in 42 countries.
|Condition or disease||Intervention/treatment|
|Neoplasms, Prostate Benign Prostatic Hyperplasia Cancer||Drug: Dutasteride Drug: Placebo|
|Study Type :||Observational|
|Actual Enrollment :||1 participants|
|Official Title:||Economic Analyses Alongside the REDUCE Clinical Trial|
|Study Start Date :||January 2010|
|Actual Primary Completion Date :||July 2010|
|Actual Study Completion Date :||July 2010|
|Men at increased risk for Prostate Cancer (PCA)||
dutasteride 0.5mg daily.
Other Name: Placebo
Men taking placebo daily
- Cost of treating prostate-related events [ Time Frame: REDUCE clinical trial, 4 year time period ]Prostate Related Events include Benign Prostatic Hyperplasia (BPH), Prostate Cancer (PCA) and Prostatitis
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01337258
|Study Director:||GSK Clinical Trials||GlaxoSmithKline|